Cell Therapy Manufacturing Market Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
The cell therapy manufacturing market is valued at USD 4.90 billion in 2024 growing at a CAGR of 9.90% during the forecast period 2024-2035. Currently, over 300 cell therapies are in various stages of clinical development, with more than 1,930 clinical studies initiated since 2019 focusing on these candidates. Several of these commercialized cell therapies have emerged as top-selling drugs in the healthcare sector. For example, Gilead Sciences reported that Yescarta achieved sales exceeding USD 1.5 billion, while Tecartus generated sales of USD 370 million in 2023. Given the substantial evidence supporting the clinical benefits and therapeutic potential of cell therapies, stakeholders are now concentrating on optimizing the manufacturing processes for these therapies. In recent years, numerous advanced automation technologies and platforms have been developed, demonstrating the potential to significantly lower manufacturing costs, thus making these products more affordable. One n
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences to Present at Upcoming Investor EngagementsBusiness Wire
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Truist Financial Co. from $83.00 to $97.00. They now have a "hold" rating on the stock.MarketBeat
- Gilead Sciences, Inc. (NASDAQ: GILD) was downgraded by analysts at Maxim Group from a "buy" rating to a "hold" rating.MarketBeat
- Gilead Sciences Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target raised by analysts at Oppenheimer Holdings Inc. from $95.00 to $105.00. They now have an "outperform" rating on the stock.MarketBeat
GILD
Earnings
- 11/6/24 - Beat
GILD
Sec Filings
- 11/7/24 - Form 4
- 11/7/24 - Form 4
- 11/6/24 - Form 144
- GILD's page on the SEC website